Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.305 USD | -3.65% |
|
-4.01% | -63.86% |
26/06 | EyePoint Pharmaceuticals, Inc. Highlights Duravuyu Clinical and Regulatory Progress and Pipeline Innovation At R&D Day 2024 | CI |
26/06 | Transcript : EyePoint Pharmaceuticals, Inc. - Special Call |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-63.86% | 45Cr | |
+57.05% | 81TCr | |
+39.52% | 62TCr | |
-6.83% | 35TCr | |
+7.50% | 29TCr | |
+13.74% | 24TCr | |
+13.83% | 22TCr | |
-0.49% | 22TCr | |
+7.89% | 17TCr | |
-2.45% | 16TCr |
- Stock Market
- Equities
- EYPT Stock
- News EyePoint Pharmaceuticals, Inc.
- Eyepoint Pharmaceuticals Insider Sold Shares Worth $660,370, According to a Recent SEC Filing